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SUMMARY 
SETTING:  Clinical trial in 762 patients with newly diagnosed pulmonary tuberculosis 
in Hong Kong.  After an initial 2 months of a four-drug intensive phase consisting of 
streptomycin, isoniazid, rifampicin and pyrazinamide (SHRZ), a random allocation was 
made to a continuation phase of once-weekly rifapentine + isoniazid (HRp1), HRp1 given 
in 2 of every 3 weeks (HRp1.2/3), or to three times weekly isoniazid + rifampicin (HR3). 
OBJECTIVE:  Final report evaluating relapse rates after 4.5 years follow-up and the 
prognostic influence of sputum culture at 2 months. 
METHODS:  Kaplan-Meier analysis of relapse rates and Cox proportional hazards 
analysis of prognostic factors. 
RESULTS: The two rifapentine regimens, HRp1 and HRp1.2/3 had similar final rates of 
adverse events (relapses or 1 failure) of 10.8% and 11.7%, respectively, compared to 
4.2% for the HR3 regimen (p = 0.02 and 0.009, respectively).  In the initial univariate 
proportional hazards analysis, adverse events were significantly related to the regimen, 
age, sex, pretreatment radiographic extent of disease and cavitation, and also to sputum 
culture at 2 months.  In the final multivariate analysis, after step-wise removal of non-
significant factors, adverse events were related only to the regimen, sex of patients and 
pretreatment radiographic extent of disease.   Elderly male patients were more at risk of 
an adverse event as were those with more severe disease.  Adverse events occurred at life 
table rates of 9.0% in patients with drug-sensitive strains and in 8.9% of those with 
initially isoniazid-resistant organisms at 4.5 years of follow-up. 
CONCLUSIONS: The two rifapentine regimens were unsatisfactory because of their 
high incidence of adverse events.  Older males have a poor immune status.   Isoniazid 
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appeared not to contribute to preventing relapse.  Further studies with increased 
rifapentine dosage are necessary.  
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Initial1 and interim2 reports of the first clinical trial of once-weekly rifapentine and 
isoniazid in the continuation phase of the treatment of pulmonary tuberculosis in Hong 
Kong have shown a substantially higher relapse rate after chemotherapy in the two 
rifapentine arms than in the control rifampicin arm.  Furthermore, evidence from patients 
with initial isoniazid-resistant strains and the results of isoniazid acetylation genotyping 
has indicated that isoniazid had no bactericidal role during the continuation phase.  The 
present report has been prepared after the completion of the 5-year study period (4.5 
years of follow-up after treatment).  An analysis of the prognostic value of pretreatment 
assessments has been made.  Also included are the prognostic value of 2-month and 3-
month sputum culture results since there is current interest in the use of surrogate markers 
for relapse as adjuncts to the development of new anti-tuberculosis drugs.3 
 
METHODS 
Rifapentine is a rifamycin which shows complete cross-resistance with rifampicin but has 
a long half-life in the mouse and in humans.4  Rifapentine of Chinese manufacture was 
used in the clinical trial because no drug of Western manufacture was then available.5   Of 
the 672 patients admitted, 592 satisfied initial criteria and were treated with an initial 2 
months of streptomycin + rifampicin + isoniazid + pyrazinamide given 3-times weekly, 
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the standard frequency of drug administration in the Hong Kong government service.  
They were then randomly allocated to one of three regimens given for 4 months: (1) the 
control regimen of isoniazid + rifampicin 3-times weekly (HR3); (2) isoniazid + 
rifapentine once weekly (HRp1); (3) HRp1 with the weekly dose omitted every third week 
to simulate poor compliance (HRp1.2/3).  Before each dose of rifapentine, patients ate a 
fast-food sandwich shown to promote its absorption efficiently.6   Standard drug doses 
were given including a 600 mg dose of rifapentine.  Because of its poor bioavailability, 
the dose of 600 mg rifapentine used throughout treatment for the first 62% of patients 
was increased to 750 mg in the last 38%.7  These doses gave serum concentrations similar 
to 450 mg and then to 600 mg of well absorbed drug manufactured by Merrell Dow 
Lepetit.   The latter preparation appears to have produced concentrations in the blood of 
volunteers at least as high as the preparation produced currently by Hoechst Marion 
Rousell.8   Sputum was examined by smear and culture monthly during the 6 months of 
treatment and for 18 months after treatment ceased; thereafter sputum was examined 3-
monthly and eventually 6-monthly until a 4.5-year follow-up had been completed.  The 
47 adverse events were either a radiographic failure in 1 HRp1 patient at 6 months or a 
relapse (usually bacteriological and radiographic) during follow-up in 46 patients. 
Statistical procedures  
Pretreatment assessments for  cavitation were scored as present (1) or not (0). 
Radiographic extent of disease was scored relating the combined area of lesions to the 
area of the right upper lobe (RUL):  the scores were 1, where the lesional area was less 
than RUL, 3, where it was greater than RUL and 2 where is was intermediate between 1 
and 3.  The number of colonies on Lowenstein Jensen slopes were scored as 1 for 1-3 
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colonies, 2 for 4-10 colonies, 3 for 10-19 colonies, 4 for 20 to 100 colonies, 5 for 
innumerable discrete colonies and 6 for confluent growth.  Pairs of sputum culture were 
obtained from each patient pretreatment and at 2 and 3 months.  The result on the first 
sputum collected was used in analysis except that if it was contaminated or otherwise 
unavailable, the result from the second specimen was substitued.  The results in the study 
were entered into and analysed in EPI INFO version 6.04b.9   The Kaplan-Meier and Cox 
proportional hazard analyses was done in Stata release 6 (Stata Corp., College Station, 
Texas).  Notification rates and numbers of notifications by age and sex were taken from 
the Annual Report 1995 of the Chest Service of the Department of Health, Hong Kong.  
 
RESULTS  
After exclusion of 35 patients for drug toxicity, 18 who defaulted during treatment and 5 
not followed for miscellaneous reasons, there remained 534 patients available for follow-
up after the end of treatment.  During the follow-up period of 4.5 years (54 months), there 
was a slow loss of patients due mainly to default, including travel to the Chinese 
mainland, and also 6 patients who died from non-tuberculous causes.   Those available 
were 90.1% of the original total at 12 months, 84.6% at 24 months and 75.3% at 54 
months (Table 1).   No additional adverse events had occurred  since the 47 described in  
the interim report 2, consisting of 1 failure at 6 months and  46 relapses during the follow-
up.  The life table proportions of adverse events were 3.6%, 7.9% and 10.5% at 12 
months after the end of treatment in the HR3, HRp1 and HRp1.2/3 regimens, respectively.  
These proportions widened to 4.2%, 10.2% and 11.1%, respectively, at 24 months.  The 
Kaplan-Meier curves for the probability of no adverse event are shown in Fig 1. Log rank 
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tests on the curves found significant differences between the rates in the HR3 and either 
the HRp1 (p = 0.02) or the HRp1.2/3 (p = 0.009) regimens but not between the HRp1 and 
the HRp1.2/3 regimens (p = 0.7). 
Prognosis analysis 
The initial results of the univariate proportional hazards analysis indicate significant 
effects of the regimens, the age of patients, their sex, the pretreatment radiographic extent 
of disease and presence of cavitation, and the culture results at 2 months (Table 2).   After 
step-wise discard of those factors that were not significant, the only factors that remained 
as independently significant in the final multivariate analysis were the regimens, the sex 
of patients and their pretreatment radiographic extent of disease.  No interaction was 
found between the findings in the three regimens, implying that the factors had similar 
effects in all of them.  This conclusion is supported by a further analysis of the results in 
the two rifapentine-containing regimens alone, which yielded similar results to those in 
the main analysis (Table 2). 
   Separate analyses were then done on factors that achieved significance in the initial 
model.  The number of adverse events according to pretreatment radiographic extent, age 
and sex are set out in Table 3.  Taking the sex association first, adverse events were 
found in 41 (11.9%) of 346 male patients but in only 6 (3.2%) of 188 female patients. 
The number of cases in the study and the adverse events in males are compared with the 
notification rates per 100,000 population (scaled up by a factor of 50 to aid visibility in 
the graph) and the number of notifications in Hong Kong in 1995 (at the end of the 
intake) by age in Fig 2.   The notification rates and the notifications in the two sexes have 
closely similar shapes with similar rates and numbers up 30 years.  Thereafter, both rates 
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and numbers diverge with less disease in females than in males.   The number of cases in 
the study also has the same pattern, though the divergence between males and females 
appears slightly greater.  The numbers of adverse events show rather different patterns.   
In males, the curve for adverse events rises after the age of 40 years when the number of 
cases is slowly falling, indicating that relapses are more frequent in the older age groups 
(see also Table 3). There are insufficient adverse events in females to make a similar 
comparison, though 4 of the 6 adverse event happened in patients below 45 years.  A 
possible causative factor is that the pretreatment radiographic extent of disease increased 
with increasing age in males by a mean increase of 0.0081 in the extent score for every 
year of age (F1,342 = 12.8;  P<0.001). No asssociation between  extent of disease and age 
was found in females (F1,184 = 0.8; NS). The effect of pretreatment radiographic extent of 
disease is set out in Table 4.  Adverse events occurred in 3.4% of 298 patients with a 
grade of 1, increasing to 24.6% of 57 patients with a grade of 3.  The association was 
found in all three regimens.  
  Table 5 shows that adverse events occurred in 8 (17%) of 46 patients with a positive 
culture at 2-months and in 35 (7.3%) of 476 patients with a negative culture.  The 
association is evident in all 3 regimens. No additional weight was added to the 
association by considering the number of colonies found in the cultures.   Even though 
the hazard ratio was higher for positive cultures at 3 months than at 2 months (Table 2), 
there were insufficient positive cultures at 3 months for any association with adverse 
events to be assessable.  
  Considering next the relationship between adverse events and the sensitivity to isoniazid 
of pretreatment cultures, there was an unfortunate error, which did not affect the 
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conclusions, in the relevant table previously published in the interim report.2  Although 
the number of adverse events remains the same, the correct figures are set out in Table 6.  
There is no suggestion that adverse events occurred more frequently in the 23 patients 
with initial resistance to isoniazid, including 11 with additional resistance to streptomycin 
(Log rank test for equality of survival: 2 = 0.00, p = 0.995).  Life table rates of adverse 
events in all 3 regimens were 7.31%, 8.56% and 9.00% in those with sensitive organisms 
at follow-up for 12, 24 and 54 months, respectively, while a closely similar rate of 8.90% 
was found at each of these months in those with initially resistant organisms.  
 
DISCUSSION 
The life-table rates of adverse events were higher after a 4.5-year follow-up in the HRp1 
series (10.8%) and the HRp1.2/3 (11.7%) than in the HR3 series (4.2%).  There is a great 
similarity in life table rates found at the 2-year follow-up in the three available clinical 
trials.  Thus in the present Hong Kong study, the rates in the HRp1 and the control HR3 
regimens were 10.2% and 4.2%, respectively, whereas the corresponding rates in the 
Hoechst Marion Rousell licensing study 008 were 12.4% in the HRp1 and 6.6% in the 
HR2 (dosage twice a week) regimens, and in CDC study 22, they were 9.2% in the HRp1 
and 4.5% in the HR2 regimen.  These results indicate that the dose of 600 mg rifapentine 
used in all three studies was inadequate and that studies of higher doses of rifapentine are 
necessary. 
  In the prognosis analyses, a striking finding was the strong association, in the initial 
univariate analysis, between adverse events and the sex and age of patients and between 
adverse events and sex alone in the final multivariate analysis (Table 2).  A similar strong 
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association with sex was found in study 008 where, as in Hong Kong, male patients were 
much more likely than female patients to have a relapse.  We will define as 
“immunological”all factors leading to disease that arise within the patient, and as 
“environmental” all factors outside the patient such as the chance of meeting someone 
with infectious tuberculosis.  Clearly the chance of a relapse can only be due to 
immunological factors.  Fig 2 and Table 2 show that immunological factors leading to 
relapse are greater in males than in females and also in males over the age of 40 years 
than in those younger.  This propensity is accompanied by the occurrence of more severe 
disease at diagnosis in older males; the association accounts for the disappearance of age 
during step-wise analysis.  As the immunological propensity is likely to extend to the 
general population and the sex/age discrepancy is greater in the occurrence of adverse 
events than in notification rates, there is some evidence that immunological factors are 
more important than environmental factors in causing the greater tendency for older 
males to develop tuberculosis shown in the notification rates in Fig 2. 
A number of factors are interlinked in leading to adverse events.  These are radiographic 
extent of disease, the presence of cavitation and culture positivity at 2 months and 3 
months.  The most important of these was extent of disease, and the others were therefore 
eliminated during the step-wise multivariate analyses.  This does not however, mean that 
their associations with adverse events do not exist.  There is a current search for surrogate 
markers for relapse to enable rapid assessment of new anti-tuberculosis drugs.  The high 
hazard ratio of 2.49 for 2-month bacteriology supports the potential importance of this 
assessment as a surrogate marker.  A previous investigation of prognostic factors in 
studies of short-course chemotherapy in Hong Kong found that of pretreatment factors, 
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age, but not sex, and colony counts of sputum were most predictive of relapse, older 
patients with high colony counts being more likely to relapse.  Smear and culture results 
at 2 months were also highly predictive of relapse. 
Initial bacillary isoniazid resistance had no apparent influence on the occurrence of 
adverse events.  This finding together with the evidence, previously published, that the 
distribution of isoniazid genotypes is closely similar in those with and without an adverse 
event provides evidence that isoniazid does not contribute to the bactericidal action of the 
continuation phase of the regimen.  In previous studies on once-weekly chemotherapy, 
clear-cut associations were found with regimens of isoniazid plus streptomycin or 
rifampicin which started early in treatment.  No such association was however found with 
relapse occurring after treatment in a study of intermittent ethambutol/isoniazid, 
indicating the greater importance of the bactericidal activity of isoniazid early rather than 
late in treatment.  A weak association has been found in CDC study 22 between 5-hr 
isoniazid plasma concentrations and adverse events in a sample of 152 patients (p=0.02), 
but no association was evident with the AUC.  The disagreement with our findings 
suggests either that isoniazid has a very small influence on adverse events that was not 
detected in our study or that the sample of 142 patients in study 22 was slightly biased by 
selection of only the 5-hr plasma results, or by chance.  It would seem unlikely that the 
discrepancy could be due to differences in the patient populations in the two studies in 
their response to chemotherapy. 
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Fig 1  Kaplan-Meier graph of adverse treatment events in the three regimens 
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Table 1   Patients available and life-table rates of adverse events during follow-up 
 
Follow-up HR3 HRp1 HRp1.2/3 Total available 
period  Adverse  Adverse  Adverse Adverse 
(months) Avail. No. % Avail. No. % Avail. No. % No. % 
0 172 0 0 179 1 0.5 183 0 0 534 100 
6 166 5 3.0 169 10 5.6 163 17 9.4 498 93.3 
12 160 6 3.6 163 14 7.9 158 19 10.5 481 90.1 
24 152 7 4.2 151 18 10.2 149 20 11.1 452 84.6 
36 141 7 4.2 145 19 10.8 143 21 11.7 429 80.3 
54 133 7 4.2 140 19 10.8 129 21 11.7 402 75.3 
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Table 2 Results of proportional hazards analysis 
 
Variable  Hazard ratio 95% CL p 
Initial results 
(univariate analysis)  
   
Regimen    
HR3 1.0   
HRp2 2.65 1.11 - 6.30  
HRp1.2/3 2.96 1.26 - 6.97 0.04 
Age 1.03 1.01 - 1.05 0.001 
Sex    
Female 1.0   
Male 3.96 1.68 - 9.34 0.002 
Body weight 0.99 0.95 - 1.03 0.7 
Pretreatment    
Radio. extent 2.82 1.94 - 4.09 <0.001 
Cavitation 1.77 1.00 - 3.14 0.05 
Bacteriology 1.08 0.87 - 1.34 0.5 
INH resistance 1.00 0.24 - 4.14 1.0 
2 mth pos. culture 2.49 1.16 - 5.33 0.02 
3 mth pos. culture 3.54 0.86 – 14.59 0.08 
Final results 
(multivariate analysis) 
   
Regimen    
HR3 1.0   
HRp1.2/3 2.98 1.25 – 7.12  
HRp1.2/3 2.82 1.20 – 6.65 0.03 
Sex    
Female 1.0   
Male 3.83 1.62 – 9.02 0.002 
 (3.92 1.54 – 10.01 0.004)* 
Pretreatment    
Radio. extent 2.90 1.98 – 4.25 <0.001 
 (3.03 2.00 – 4.59 <0.001)* 
 
* Analysis of combined results in rifapentine regimens (Rp1 & Rp1.2/3) only. 
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Table 3   Adverse events by radiographic extent of disease (radio.extent), age and sex 
 
   Male   Female 
 
 
Age 
 
 
No. 
Mean 
radio. 
extent 
 
Adverse 
events 
 
 
No. 
Mean 
radio. 
extent  
 
Adverse 
events 
10 - 19 17 (1.50)* 3 20 1.65 0 
20 - 29 83 1.31 3 69 1.46 1 
30 - 39 73 1.55 4 60 1.37 3 
40 - 49 60 1.71 15 23 1.36 1 
50 - 59 46 1.65 5 9 (1.44) 0 
60 - 69 55 1.73 9 7 (2.00) 1 
70 - 79 11 (1.82) 2 0 - 0 
80 - 89 1 (1.00) 0 0 - 0 
Total 346  41 188  6 
       
  * Percentages in parenthesis based on less than 20 patients 
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            Table 4   Adverse events by radiographic extent of disease and regimen 
 
 HR3 HRp1 HRp1.2/3 All 
Radiographic 
extent 
Total 
patients 
Adverse 
events 
Total 
patients 
Adverse 
events 
Total 
patients 
Adverse 
events 
Total 
patients 
Adverse events 
  No.         % 
0 0 0 1 0 1 0 2 0 (0)* 
1 98 2 97 3 103 5 298 10 3.4 
2 54 3 65 11 54 9 173 23 13.3 
3 18 2 15 5 24 7 57 14 24.6 
Total 170 7 178 19 182 21 530 47 8.9 
 
* Percentage in parenthesis based on less than 20 patients 
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Table 5   Adverse events according to 2-month culture result 
 
 Adverse Total Culture No. of colonies in cultures 
Regimen event patients Neg. Pos. 
  No.       % 
1-3 4-19 20-100    >100 
HR3 Yes 6 4 2 33 0 0 2 0 
 No 161 149 12 7.5 4 2 5 1 
HRp1 Yes 19 16 3 16 0 0 3 0 
 No 158 146 12 7.6 4 0 7 1 
HRp1.2/3 Yes 21 18 3 14 2 0 1 0 
 No 157 146 11 4.5 3 1 6 1 
All Yes 46 38 8 17 2 0 6 0 
 No 476 441 35 7.3 11 3 18 3 
 
 21 
Table 6   Adverse events in patients initially sensitive or  
resistant to isoniazid (INH) 
 
Pretreatment 
 
HR3 HRp1 + HRp1.2/3 
susceptibility n % n % 
INH-sensitive     
Adverse event 7 (4.2) 3.8 (11.0) 
Total 165  346  
INH-resistant     
Adverse event 0 (0.0) 2 (12.5) 
Total 7  16  
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Fig 2  Notification rates of pulmonary tuberculosis per 5,000,000 of population in Hong Kong (top curves),   notification numbers in Hong Kong 
(2nd from top), cases in the study (3rd from top) and numbers of adverse events (bottom curves) by age and sex.  Males: open symbols. Females: 
closed symbols. 
 
